Novel chromophores for polymeric thin films and optical waveguides and devices comprising the same
申请人:CORNING INC.
公开号:EP1772458A2
公开(公告)日:2007-04-11
The invention is directed to chromophores having novel electron withdrawing groups and novel bivalent cyclic bridges and to optical waveguides and optical devices having polymeric thin films which contain the novel chromophores.
Synthesis of new 2-substituted 2,5-dihydrofuranone derivatives and their chemical transformations
作者:A. A. Avetisyan、A. G. Alvandzhyan、K. S. Avetisyan
DOI:10.1134/s1070428009120240
日期:2009.12
Pseudo-donor-containing second-order nonlinear optical chromophores with improved stability and electro-optic polymers covalently incorporating the same
申请人:Wang Chuanguang
公开号:US20070073034A1
公开(公告)日:2007-03-29
Pseudo-donor-containing second-order nonlinear optical chromophores with improved stability and electro-optic polymers covalently incorporating the same are described.
[EN] MOLECULES RELATED hERG Ion CHANNELS AND THE USE THEREOF<br/>[FR] MOLÉCULES ASSOCIÉES À DES CANAUX IONIQUES HERG ET LEUR UTILISATION
申请人:CORNING INC
公开号:WO2011081970A2
公开(公告)日:2011-07-07
Disclosed are compounds having structural formula (I, II) or a pharmaceutically acceptable sale, solvate, clathrate, or prodrug thereof, wherein R1, R2, R3, R6, R5, and R4 are defined herein. These compounds can be useful as therapeutic agents for modulating hERG ion channels, and for improving prevention and treatment of hERG associated cardiac repolarization disorders.
[EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE TROUBLES PATHOLOGIQUES ASSOCIÉS À GPR35 ET/OU AU COMPLEXE GPR35-HERG
申请人:CORNING INC
公开号:WO2012012278A2
公开(公告)日:2012-01-26
Disclosed are compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically related to GPR35, and/or GPR35-hERG signaling complex. For example, disclosed are compounds for preventing and/or treating diseases which are pathophysiologically related to GPR35 in a subject.